ATE353214T1 - Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung - Google Patents

Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung

Info

Publication number
ATE353214T1
ATE353214T1 AT04741636T AT04741636T ATE353214T1 AT E353214 T1 ATE353214 T1 AT E353214T1 AT 04741636 T AT04741636 T AT 04741636T AT 04741636 T AT04741636 T AT 04741636T AT E353214 T1 ATE353214 T1 AT E353214T1
Authority
AT
Austria
Prior art keywords
antithrbotic
antiphlogistic
cerivastatin
rosuvastatin
fluvastatin
Prior art date
Application number
AT04741636T
Other languages
English (en)
Inventor
Francesca Benedini
Ennio Ongini
Soldato Piero Del
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Application granted granted Critical
Publication of ATE353214T1 publication Critical patent/ATE353214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04741636T 2003-05-27 2004-05-24 Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung ATE353214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03101530 2003-05-27

Publications (1)

Publication Number Publication Date
ATE353214T1 true ATE353214T1 (de) 2007-02-15

Family

ID=33483985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741636T ATE353214T1 (de) 2003-05-27 2004-05-24 Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung

Country Status (22)

Country Link
US (4) US7166638B2 (de)
EP (1) EP1626716B1 (de)
KR (1) KR101136434B1 (de)
CN (1) CN1794987B (de)
AR (1) AR044561A1 (de)
AT (1) ATE353214T1 (de)
AU (1) AU2004243443B2 (de)
BR (1) BRPI0410049A (de)
CA (1) CA2527168C (de)
CY (1) CY1107614T1 (de)
DE (1) DE602004004652T2 (de)
DK (1) DK1626716T3 (de)
ES (1) ES2280978T3 (de)
MX (1) MXPA05012755A (de)
NO (1) NO20056152L (de)
NZ (1) NZ543086A (de)
PL (1) PL379019A1 (de)
PT (1) PT1626716E (de)
RU (1) RU2362770C2 (de)
SI (1) SI1626716T1 (de)
WO (1) WO2004105754A1 (de)
ZA (1) ZA200509460B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070053214A (ko) 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
KR20080097989A (ko) * 2006-02-03 2008-11-06 니콕스 에스. 에이. 근위축증 치료를 위한 의약의 니트록시 유도체의 용도
EP1889617A1 (de) * 2006-07-11 2008-02-20 Freie Universität Berlin Triphenylsubstituierte fünfgliedrige Heterocyclen und deren Verwendung als Antikreb- und entzündungshemmende Mittel
AU2008238143A1 (en) * 2007-04-13 2008-10-23 Nicox S.A. Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
EP2164484A1 (de) * 2007-06-25 2010-03-24 Nicox S.A. Verwendung von stickoxid freisetzenden statinen bei der behandlung von pulmonaler arterieller hypertonie
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
JP2011521992A (ja) * 2008-06-06 2011-07-28 ニコックス エス エイ アトルバスタチン４−（ニトロキシ）ブチルエステルおよび脂質低下剤を含む組成物
US7807716B2 (en) * 2008-09-24 2010-10-05 Oral Delivery Technology Ltd. Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use
CN101613284B (zh) * 2009-06-26 2013-05-08 四川抗菌素工业研究所有限公司 洛伐他汀、辛伐他汀和辛伐他汀-6-氧化物的硝基氧基衍生物及其制备方法
EP2371404A3 (de) 2010-03-30 2014-08-20 Biotronik AG Medizinisches Implantat mit einer Beschichtung bestehend aus oder enthaltend mindestens einen Nitro-Statin-Wirkstoff
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
WO2014111957A1 (en) 2013-01-21 2014-07-24 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents
EP2983711A4 (de) 2013-04-08 2016-11-23 Cytodyn Inc Felinisierte antikörper und verfahren zur behandlung von retrovireninfektionen bei katzen
EP2949324A1 (de) 2014-05-27 2015-12-02 Consorci Institut Catala de Ciencies Cardiovasculars Prävention und/oder Behandlung von Ischämie-/Reperfusionsschäden
CN104327057B (zh) * 2014-10-17 2017-01-18 上海应用技术学院 多取代吲哚类他汀内酯脱水化合物及其用途
CN108349911B (zh) * 2015-09-07 2022-05-13 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
CN108114282B (zh) * 2016-11-28 2021-03-02 北京大学第三医院 他汀类化合物治疗缺血性疾病的用途
CN107043373B (zh) * 2017-03-31 2020-04-28 中国医药集团总公司四川抗菌素工业研究所 一种噁三唑类no供体型他汀衍生物及其制备方法和应用
CA3058250A1 (en) 2017-03-31 2018-10-04 Fundacio Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Statin for prevention/reduction of ischemia-related damage
CN106938979B (zh) * 2017-03-31 2019-08-02 中国医药集团总公司四川抗菌素工业研究所 一种no供体型他汀衍生物、制备方法和应用
EP3381452A1 (de) 2017-03-31 2018-10-03 Instituto Catalán de Ciencias Cardiovasculares (ICCC), Hospital de la Santa Creu i Sant Pau, Avda. Statin zur verhinderung/verringerung von beschädigung im zusammenhang mit ischämie
CN107098843B (zh) * 2017-03-31 2020-04-28 中国医药集团总公司四川抗菌素工业研究所 一种fk409类no供体型他汀降血脂药物衍生物及其制备方法
CN110183329B (zh) * 2019-06-19 2022-09-13 中国医药集团总公司四川抗菌素工业研究所 硝酸酯类no供体型他汀衍生物及其制备方法
CN113929609B (zh) * 2021-10-13 2024-08-23 深圳弘汇生物医药有限公司 一种调血脂的阿托伐他汀衍生物及其组合物、制备方法和医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927981D0 (en) * 1989-12-11 1990-02-14 Ici Plc Carbamoyl derivative
IE904261A1 (en) * 1990-11-26 1992-06-03 Sanofi Sa Use of a statin derivative in the treatment of eye¹complaints
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
WO1997013405A1 (en) * 1995-10-13 1997-04-17 The United States Of America, Represented By The Secretary Of Agriculture In ovo yeast treatment to diminish salmonellae populations in poultry
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1311923B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6573385B1 (en) * 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and novel intermediates thereof
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US20030100493A1 (en) 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
US20080090857A1 (en) 2008-04-17
BRPI0410049A (pt) 2006-04-25
DK1626716T3 (da) 2007-05-14
US20080096908A1 (en) 2008-04-24
DE602004004652D1 (de) 2007-03-22
NO20056152L (no) 2005-12-23
DE602004004652T2 (de) 2007-11-08
US20070072942A1 (en) 2007-03-29
CN1794987A (zh) 2006-06-28
RU2005138139A (ru) 2006-05-10
AU2004243443B2 (en) 2009-09-10
RU2362770C2 (ru) 2009-07-27
KR101136434B1 (ko) 2012-04-19
KR20060013551A (ko) 2006-02-10
HK1090295A1 (en) 2006-12-22
SI1626716T1 (sl) 2007-06-30
AU2004243443A1 (en) 2004-12-09
CN1794987B (zh) 2010-09-29
US7166638B2 (en) 2007-01-23
CA2527168C (en) 2014-08-12
WO2004105754A1 (en) 2004-12-09
NZ543086A (en) 2009-11-27
MXPA05012755A (es) 2006-02-13
US7297808B2 (en) 2007-11-20
ES2280978T3 (es) 2007-09-16
CY1107614T1 (el) 2013-03-13
AR044561A1 (es) 2005-09-21
EP1626716A1 (de) 2006-02-22
US7462716B2 (en) 2008-12-09
EP1626716B1 (de) 2007-02-07
ZA200509460B (en) 2007-04-25
PT1626716E (pt) 2007-04-30
PL379019A1 (pl) 2006-06-26
US20050165084A1 (en) 2005-07-28
US7563909B2 (en) 2009-07-21
CA2527168A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
ATE353214T1 (de) Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung
ATE319686T1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
DE602005013491D1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
DE60327341D1 (de) Hybridmoleküle von makroliden mit steroidalen/nicht-steroidalen antientzündlich aktiven molekülen
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
DE60332798D1 (de) Verringerung des Verhältnisses von Spitzen- zu Durchschnittsleistung
DE50306327D1 (de) Als aerosol versprühbare w/o-emulsionen
ATE438639T1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
ATE345108T1 (de) Kosmetische zusammensetzungen enthaltend resveratrol und retinoide
ATE370958T1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE60321043D1 (de) Biphenylderivate und deren verwendung als fungizide
DE60133831D1 (de) Verwendung von cci-779 als antineoplastisches mittel
DE60333311D1 (de) Kosmetische zusammensetzung
ATE420084T1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
DE60311694D1 (de) Kosmetische Zusammensetzung
DE602004010708D1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
DE602004024338D1 (de) Pflanzenextrakt und seine pharmazeutische und kosmetische verwendung
DE60039598D1 (de) Pharmazeutische zusammensetzungen von erythropoietin
DE60028071D1 (de) Kosmetische mittel enthaltend kickererbsen-extrakt und retinoide
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
ATE527983T1 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an partikulären uv-filtersubstanzen und alkylnaphthalaten
DE60302152D1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
DE60218860D1 (de) Polymerisate und ihre synthese

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1626716

Country of ref document: EP